Abstract
Thyroid cancer occurs three times more frequently in females than in males, and in females the incidence decreases after menopause. This gender difference suggests that the growth and progression of thyroid cancer may be influenced by female sex hormones, particularly estrogens. Experimental data have clearly demonstrated that estrogens can influence cancer cell growth. The action of estrogens on target sites is mediated through related but distinct estrogen receptors, designated estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), both of which are known to be expressed in thyroid cancer cells. The proliferation of thyroid cancer cells is promoted by an ERα agonist, whereas the proliferation is reduced by the enhanced expression of ERβ or by an ERβ agonist. When ERβ is down-regulated, the proliferation of thyroid cells is significantly increased. Studies have shown that the expression of ERα in thyroid cancer cells is increased while the expression of ERβ is either very low or absent. In conclusion, it appears that estrogens have opposite effects on the growth of thyroid cancer cells, depending on the balance between ERα and ERβ in the cells. The modulation of ERα and ERβ and the intervention of their pathways may open up new potential targets for the treatment of thyroid cancer.
Keywords: Estrogen, estrogen receptors, thyroid, cancer, proliferation, apoptosis
Current Cancer Drug Targets
Title: Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Volume: 8 Issue: 5
Author(s): George G. Chen, Alexander C. Vlantis, Qiang Zeng and C. Andrew van Hasselt
Affiliation:
Keywords: Estrogen, estrogen receptors, thyroid, cancer, proliferation, apoptosis
Abstract: Thyroid cancer occurs three times more frequently in females than in males, and in females the incidence decreases after menopause. This gender difference suggests that the growth and progression of thyroid cancer may be influenced by female sex hormones, particularly estrogens. Experimental data have clearly demonstrated that estrogens can influence cancer cell growth. The action of estrogens on target sites is mediated through related but distinct estrogen receptors, designated estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), both of which are known to be expressed in thyroid cancer cells. The proliferation of thyroid cancer cells is promoted by an ERα agonist, whereas the proliferation is reduced by the enhanced expression of ERβ or by an ERβ agonist. When ERβ is down-regulated, the proliferation of thyroid cells is significantly increased. Studies have shown that the expression of ERα in thyroid cancer cells is increased while the expression of ERβ is either very low or absent. In conclusion, it appears that estrogens have opposite effects on the growth of thyroid cancer cells, depending on the balance between ERα and ERβ in the cells. The modulation of ERα and ERβ and the intervention of their pathways may open up new potential targets for the treatment of thyroid cancer.
Export Options
About this article
Cite this article as:
Chen G. George, Vlantis C. Alexander, Zeng Qiang and van Hasselt Andrew C., Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133150
DOI https://dx.doi.org/10.2174/156800908785133150 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Anthocyanins: Chemical Properties and Health Benefits: A Review
Current Nutrition & Food Science Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties
Current Medicinal Chemistry Transthyretin and the Systemic Inflammatory Response
Current Nutrition & Food Science Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine p38 MAP Kinase Interacts with and Stabilizes Pancreatic and Duodenal Homeobox-1
Current Molecular Medicine Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Serum Cortisol, Hepcidin and Thyroid Hormone Levels in Neonates with Late-Onset Sepsis; Methodological Issues on Diagnostic and Prognostic Studies
Infectious Disorders - Drug Targets Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Chrysin Induces Apoptosis in Peripheral Blood Lymphocytes Isolated from Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Female Immunocontraceptive Vaccine - Present Status and Future Perspectives
Current Women`s Health Reviews